share_log

ASLAN Says 'The Eblasakimab 400mg Q4W Dosing Arm Did Not Meet the Primary or Secondary Endpoints With Statistical Significance'

ASLAN Says 'The Eblasakimab 400mg Q4W Dosing Arm Did Not Meet the Primary or Secondary Endpoints With Statistical Significance'

ASLAN 说 “Eblasakimab 400mg Q4W 给药组没有达到具有统计学意义的主要或次要终点”
Benzinga ·  2023/07/06 07:59

ASLAN Says 'The eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints with statistical significance'

ASLAN 说 “eblasakimab 400mg Q4W 给药组没有达到具有统计学意义的主要或次要终点”

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发